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Abstract: Queuosine (Q) is a hypermodified RNA nucleoside
that is found in tRNAHis, tRNAAsn, tRNATyr, and tRNAAsp. It is
located at the wobble position of the tRNA anticodon loop,
where it can interact with U as well as C bases located at the
respective position of the corresponding mRNA codons. In
tRNATyr and tRNAAsp of higher eukaryotes, including humans,
the Q base is for yet unknown reasons further modified by the
addition of a galactose and a mannose sugar, respectively. The
reason for this additional modification, and how the sugar
modification is orchestrated with Q formation and insertion, is
unknown. Here, we report a total synthesis of the hyper-
modified nucleoside galactosyl-queuosine (galQ). The avail-
ability of the compound enabled us to study the absolute levels
of the Q-family nucleosides in six different organs of newborn
and adult mice, and also in human cytosolic tRNA. Our
synthesis now paves the way to a more detailed analysis of the
biological function of the Q-nucleoside family.
In all three domains of life, RNA contains next to the
canonical bases (A, C, G, and U) a large variety of modified
nucleosides.[1] Most of these are chemically simple derivatives
of the canonical nucleosides. They often carry methylations at
various positions of the heterocycle or the sugar, but others
are heavily modified, involving multistep biosynthesis path-
ways. Queuosine 1 (Q) is one of the most complex of these so-
called hypermodified nucleosides. (Figure 1). It is found in
a large number of different species and also present in the
cytosolic and mitochondrial tRNATyr, tRNAAsp, tRNAHis, and
tRNAAsn of humans.[2–8] Interestingly, in the human cytosolic
tRNATyr and tRNAAsp, Q is further modified with galactose
(galQ) and mannose (manQ), respectively.[9, 10] In these
tRNAs, the sugar is proposed to be attached to the
homoallylic hydroxyl group of the cyclopentene ring system
that is linked to the 7-deazaheterocycle.[11] While the chemical
synthesis of Q has been achieved,[12–14] no reports exist about
the preparation of its sugar-modified derivatives galQ 2 and
manQ 3, which has hampered investigations of their biolog-
ical role. Accordingly, the exact function of galQ and manQ as
part of the human cytosolic tRNATyr and tRNAAsp is
unknown. In addition, we do not know to which extent the
corresponding tRNAs are modified with different Q-family
nucleosides, and how the G/Q-exchange process and the sugar
derivatization is orchestrated. Furthermore, quantitative data
about Q-modification levels in different organs is also lacking.
To address these questions, we performed the first total
synthesis of galactosyl-queuosine 2. This allowed us to
confirm its proposed structure and to report the absolute
levels of all Q-family members in different tissues of newborn
and adult mice. Finally, we were able to measure to which
extent human cytosolic tRNAs are modified with the three Q-
family nucleosides.
Figure 1. Depiction of the hypermodified RNA nucleoside queuosine
(1, Q) and of the galactosylated and mannosylated Q derivatives galQ
(2) and manQ (3) present in human cytosolic tRNATyr and tRNAAsp,
respectively.
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Galactosyl-Q 2 was constructed from three appropriately
protected parts (Figure 2): The 7-formyl-7-deazaguanosine 6
was prepared, as reported by us, with Bz-protected hydroxyl
groups at the ribose, and a pivaloylate protection group at the
2-amino residue.[14] The galactose sugar was introduced as
a TBS- and 2-chloroisobutyryl-protected trichloroacetimidate
4, and the cyclopentene unit 5 was used with Fmoc-protected
allyl amine and a TBS-protected allylic alcohol. We choose
the 2-chlorobutyryl protecting group for the sugar-donor 4
because of its bulkiness in order to avoid unwanted orthoester
formation as the main product of the glycosylation reaction,
a strategy reported by Szpilman et al.[15]
The galactosyl-donor 4 itself was prepared from d-galactal
7, which was first TBS-protected (Scheme 1A).[16] cis-Dihy-
droxylation of the double bond from the sterically less
shielded side furnished compound 8.[17] This step was followed
by protection of the two newly introduced hydroxyl groups
with 2-chloroisobutyric acid to give the galactose-donor
precursor 9. Deprotection of the anomeric hydroxyl group
with hydrazine provided the galactose precursor with a free
anomeric hydroxyl group which was subsequently converted
into the trichloroacetimidate donor 4 using a standard
procedure.
Scheme 1B shows the synthesis of the protected 5(S)-
amino-3(S),4(R)-dihydroxycyclopent-1-ene 5. The starting
point was mannose 10,[18] which was converted as reported
into the double-acetonide-protected mannofuranoside 11
with an acetyl-protected anomeric center in two steps.
Selective cleavage of the acetonide protecting group at the
primary hydroxyl group, followed by an orthoester-based
elimination, allowed introduction of a terminal double bond
(12). Anomeric deprotection, followed by a Wittig reaction,
provided the precursor 13 for the ring-closing metathesis
reaction. The free hydroxyl group in 14 was then the starting
point for an Overman rearrangement, providing the amine
protected as the trichloroacetamide-protected amine 15.[19]
Cleavage of this protecting group with NaOH was followed by
Fmoc protection of the free amine using a standard proce-
dure. We finally opened the acetal and protected the allylic
hydroxyl group selectively with TBS-OTf in DMF at 55 8C.
In this reaction, the temperature is particularly important.
When the reaction was performed at higher temperatures and
with prolonged reaction times, we noted selective protection
of the homoallylic position.
The assembly of the galQ nucleoside 2 from the pre-
cursors 4–6 is shown in Scheme 2. We first galactosylated the
cyclopentene derivative 5. This sterically demanding step was
successfully achieved by activation of the trichloroacetimi-
date with 2-chloro-6-methylpyridinium triflate in dichloro-
methane at room temperature.[15,20] We achieved selective
formation of the b-configured galactoside due to the neigh-
boring-group effect. Subsequent cleavage of the Fmoc
protection group gave product 16, which was followed by
a two-step reductive amination. First, the imine was formed in
benzene, subsequently followed by reduction of the imine
with NaBH4 in methanol to afford protected galQ 17. In
a two-step deprotection protocol, we first removed the TBS
groups with HF·NEt3, followed by cleavage of ester-type
Figure 2. Retrosynthetic analysis for galQ 2, showing the three key
precursors 4, 5, and 6.
Scheme 1. Synthesis of the key precursors 4 and 5. A) Synthesis of the
galactose precursor 4 : a) TBSCl, imidazole, DMF, 55 8C, 2 d;
b) K2OsO4·2H2O, NMO, THF, t-BuOH, H2O, rt, 4 h; c) 2-chloroisobu-
tyric acid, DIC, DMAP, 0 8C, 30 min!rt, 2 h; d) N2H4·AcOH, DMF,
40 8C to rt, 3 h; e) Cl3CCN, Cs2CO3, DCM, rt, 4 h. B) Synthesis of the
cyclopentene precursor 5 : a) 2,2-dimethoxypropane, acetone, p-TsOH,
rt, 1 h; b) Ac2O, pyridine, 0 8C!rt, 18 h; c) aq. AcOH (66%), 55 8C,
4 h; d) triethylorthoformate, 100 8C, 30 min; e) Ac2O, 130 8C, 5 h; f) t-
BuOK, MeOH, 20 min; g) NaH, DMSO, Ph3PMeBr, THF, rt!68 8C,
2 h; h) Grubbs(I) catalyst, DCM, rt, 26 h; i) Cl3CCN, DBU, DCM, rt,
20 min; k) o-xylene, 150 8C, 5 h; l) NaOH, MeOH, rt, overnight;
m) Fmoc-OSu, NaHCO3, H2O, 1,4-dioxane; n) AcOH, H2O, EtOAc,
50 8C, 24 h; o) TBSOTf, DMF, 55 8C, 15 min.
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protecting groups under Zempln conditions. For the cleav-
age of the pivaloyl amide protecting group, we needed to use
0.5m NaOMe in methanol. This strategy provided the target
compound 2 with an overall yield of 0.5% in 20 linear steps
from the mannose starting molecule for the cyclopentene
unit. The synthesis provided a sufficient amount of material
for all further investigations.
We next investigated whether our synthetic b-homoallylic
galQ 2 is identical with the natural product, because analytical
data available for galQ was very limited.[11] For this experi-
ment, we isolated total RNA from mouse liver and performed
an enzymatic digestion of the isolated RNA to the nucleoside
level. This nucleoside mixture was analyzed by HPLC-MS.
Indeed, under our HPLC conditions, we detected two signals
with the appropriate m/z value for galQ and manQ in the
extracted ion chromatogram with a retention time of around
32 and 35 min. No other peaks were present in the same m/z
range. We next co-injected our synthetic b-homoallylic galQ
2, which led to a marked increase of the second signal with
a retention time of about 35 min (Figure 3). This result
unambigously showed that our synthetic compound galQ 2
and the co-eluting natural compound with the same mass are
identical. Therefore, this natural compound is indeed a b-
galactosylated Q derivative. Taken together, our experiment
confirms the proposed chemical structure of galQ, in which
the bond between the homoallylic hydroxyl group of queuo-
sine and galactose is in b-configuration.
Having identified the HPLC retention time of galQ and
therefore also of manQ, we finally were able to determine the
absolute levels of galQ, manQ, and Q in different tissues of
newborn (postnatal day 1; pd1) and adult mice (postnatal
month 3; pm3). For an initial broad study, we measured the
respective nucleoside levels in cortex, cerebellum, liver,
kidney, heart, and spleen, using the same RNA isolation
and digestion protocol as for the co-injection experiment
(Figure 4A).
From our data it is clearly evident that the levels of all
three modifications (galQ, manQ, and Q) generally increase
with age. This effect is by far most pronounced with Q, while
galQ and manQ only show a modest increase, if at all.
Furthermore, and for all three modifications investigated, we
see differences between the six organs at the same age. Heart,
followed by brain tissues, contains the largest levels of Q and
its sugar-modified derivatives, followed by kidney, liver, and
spleen. In general, the changes of the modification levels
observed by us positively correlate with the respective organ-
specific protein-synthesis demands, as we have shown
before.[7] Nevertheless, there are some prominent outliers.
These outliers (e.g. heart tissue) seem to rather correlate with
the organ-specific density of mitochondria. It was shown
before that the Q-base in mitochondrial tRNATyr and
tRNAAsp is not sugar-modified.[8] We therefore speculate
that the organ-specific differences in the levels of galQ,
manQ, and Q are due to a combination of two independent
effects: The organ-specific protein-synthesis ratio and the
organ-specific mitochondrial density.
It is well-established that for biosynthesis of Q (and its
sugar-modified derivatives), eukaryotes have to take up the
queuine base from their diet,[21,22] mammals thereby profiting
from their gut microbiome.[23] We therefore speculate that the
low levels of Q-family nucleosides in newborn mice observed
here may be caused by a lack of queuine supply in newborn
mice, which only later establish their microbiome. Further-
more, high rates of cell divison and tissue development in
young mice may cause additional queuine supply problems.
To further study the influence of queuine availability on
Q-family modification levels, cell culture experiments were
performed: Human embryonic kidney cells (HEK 293T) were
grown either in culture medium supplemented with 20 nm
queuine (enriched medium) or in medium without additional
Scheme 2. Depiction of the galQ 2 assembly from the three key
precursors 4, 5, and 6. a) 2-Chloro-6-methylpyridinium triflate, DCM,
rt, 2 h; b) DBU, MeCN, rt, 1.25 h; c) benzene, rt, 5 h; d) NaBH4,
MeOH, 0 8C, 1 h; e) HF·NEt3, DCM, rt, 4 d; f) NaOMe, MeOH, rt, 2 d.
Figure 3. Results of a co-injection study confirming the identity of our
synthetic b-homoallylic-galQ 2 and the natural product. Depicted are
the extracted-ion chromatograms (m/z = 572.2148–572.2248) of two
HPLC-MS analyses, either with (right) or without (left) prior spiking of
the synthetic galQ 2. The exact mass [M+H]+ of galQ (and manQ) is
572.2198 u, showing a perfect match to the two MS peaks observed by
us with less than 4 ppm deviation.
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queuine (standard medium). Queuine is the substrate of the
TGT enzyme, which performs the exchange of a guanine base
by the queuine heterocycle during tRNA maturation.[24–26]
From both cell populations, cytosolic tRNATyr, tRNAAsp,
tRNAHis, and tRNAAsn were isolated and digested to the
nucleoside level. For each of these four individual tRNA
species, the number of galQ, manQ, and Q modifications per
tRNA was then determined by a mass-spectrometry-based
isotope-dilution method using the reference compound
synthesized here (see the Supporting Information).
Indeed, our data show that the extent of Q-modification in
the wobble position of cytosolic tRNATyr, tRNAAsp, tRNAHis,
and tRNAAsn is strongly dependent on queuine availability
(Figure 4B).[24] In the case of tRNATyr (galQ), tRNAHis, and
tRNAAsn (Q), the difference in modification extent between
cells grown in enriched versus standard medium is threefold,
while for tRNAAsp (manQ) it is 1.7 fold. These results are well
in line with our hypothesis and might therefore explain the
lower modification levels in newborn mice. Of note, in all of
our experiments even a sufficient queuine supply did not lead
to fully modified tRNAs. This might again be an indication of
the modification machinery lagging behind the de novo
synthesis of tRNA in highly proliferating cells.
Furthermore, we detected a Q-only-modified tRNATyr
form in our experiments lacking the galactose sugar, while
tRNAAsp was always found to be either modified with manQ
or completely unmodified. It seems that, in our experimental
setup, mannosylation of tRNAAsp may be more tightly
connected to G/Q-exchange than the galactosylation of Q-
only-bearing tRNATyr. Testing this exciting hypothesis is an
interesting starting point for future studies.
In summary, we here report the first total synthesis of the
human natural product galactosyl-queuosine 2. Our synthetic
material allowed us to confirm the proposed galQ structure by
direct comparison with natural material, and we show that
this hypermodfied nucleoside is present in all tissues of
newborn and adult mice. We furthermore report the absolute
levels of all three Q-family members in six different mouse
organs and in human cytosolic tRNAs. Taken together, our
results confirm the crucial importance of tRNA galQ and
manQ modification.
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